FDA Advisors Leave Door Open To Mix and Match COVID-19 Vaccine Boosters
Discussion also reopened the debate on allowing universal boosting with mRNA vaccines, with advisors giving FDA more leeway to allow some younger Americans to get an additional mRNA shot regardless of their occupation or underlying health conditions.
You may also be interested in...
The foundation is donating to help supply Merck/Ridgeback’s antiviral to low-income nations; also Pfizer got one step closer to full approval for booster shots of Comirnaty, while the FDA authorized Moderna and J&J boosters, and Daiichi Sankyo made progress on its own mRNA vaccine candidate. Shionogi's once-daily oral antiviral is also moving forward.
After US FDA authorization for additional COVID vaccine shots, the focus now shifts to CDC’s advisory committee, which may be concerned about variations in eligible populations, timing and dosing when it comes to giving a booster different from the primary vaccination series.
Despite lack of enthusiasm with immunobridging study data, the panel endorsed emergency use in certain at-risk populations, in part because it would be hard to turn down the Moderna booster when an identical EUA had been issued for Pfizer/BioNTech's mRNA vaccine.